Ignite Creation Date:
2025-12-24 @ 11:51 PM
Ignite Modification Date:
2026-02-25 @ 5:54 PM
Study NCT ID:
NCT03737851
Status:
COMPLETED
Last Update Posted:
2023-12-22
First Post:
2018-11-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-12-11
Start Date Type:
ACTUAL
Primary Completion Date:
2021-08-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-09-09
Completion Date Type:
ACTUAL
First Submit Date:
2018-11-06
First Submit QC Date:
None
Study First Post Date:
2018-11-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-11-14
Results First Submit QC Date:
None
Results First Post Date:
2023-12-22
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2023-12-22
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2023-12-04
Last Update Post Date:
2023-12-22
Last Update Post Date Type:
ACTUAL